National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 49689-49690 [E8-19450]

Download as PDF Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices Agenda: To discuss the training programs of the Institute. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Stephen J. Korn, PhD, Training and Special Programs Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Suite 2154, MSC 9527, Bethesda, MD 20892–9527, (301) 496–4188. Name of Committee: National Advisory Neurological Disorders and Stroke Council, Basic and Preclinical Programs Subcommittee. Date: September 18, 2008. Time: 8 a.m. to 10 a.m. Agenda: To discuss basic and preclinical programs policy. Place: National Institutes of Health, Building 31, 31 Center Drive, C Wing, Conference Room 7, Bethesda, MD 20892. Contact Person: Jill E. Heemskerk, PhD, Acting Chief, Technology Development, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Boulevard, Suite 2229, MSC 9527, Bethesda, MD 20892–9527, (301) 496– 1779, jh440o@nih.gov. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: http:// www.ninds.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: August 15, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–19449 Filed 8–21–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jlentini on PROD1PC65 with NOTICES National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President’s Cancer Panel. The meeting will be open to the public as indicated below, with attendance limited to space available. VerDate Aug<31>2005 17:12 Aug 21, 2008 Jkt 214001 Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended, because the premature disclosure of these discussions would be likely to significantly frustrate implementation of recommendations. Name of Committee: President’s Cancer Panel. Date: September 16, 2008. Open: September 16, 2008, 8 a.m.–4:15 p.m. Agenda: Environmental Factors in Cancer. Place: Hilton East Brunswick, 3 Tower Center Boulevard, East Brunswick, NJ 08816. Closed: September 16, 2008, 4:30 p.m.– 7:30 p.m. Agenda: Discussion concerning the release of the final report and recommendations from the 2007–2008 series; discussion of testimony given in open session on Environmental Factors in Cancer; consideration of thematic concepts for the 2009/2010 series. Place: Hilton East Brunswick, 3 Tower Center Boulevard, East Brunswick, NJ 08816. Contact Person: Abby Sandler, Ph.D., Executive Secretary, National Cancer Institute, National Institutes of Health, Building 6116, Room 220, MSC 8349, 6116 Executive Boulevard, Bethesda, MD 20892, 301/451–9399. Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 15, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–19448 Filed 8–21–08; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 49689 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDDK. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Diabetes and Digestive and Kidney Diseases, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDDK. Date: October 6–7, 2008. Time: October 6, 2008, 9 a.m. to 5 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, Building 10, 10 Center Drive, 9S235, Bethesda, MD 20892. Time: October 7, 2008, 9 a.m. to 4 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, Building 10, 10 Center Drive, 9S235, Bethesda, MD 20892. Contact Person: Ira W. Levin, PhD, Chief, Section on Molecular Biophysics, Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, 301–496–6844, iwl@helix.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition E:\FR\FM\22AUN1.SGM 22AUN1 49690 Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: August 15, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–19450 Filed 8–21–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Workgroup Meeting; Notice Is Hereby Given of a Meeting of the Strategic Planning Implementation Workgroup (SPIWG) Organized by the Interagency Autism Coordinating Committee (IACC) jlentini on PROD1PC65 with NOTICES The purpose of the workgroup meeting is to discuss future budgetary requirements for the IACC Strategic Plan for Autism Spectrum Disorder (ASD) Research. The workgroup findings will be forwarded to the IACC for consideration and discussion at the next committee meeting on November 21, 2008. Audio of this workgroup meeting will be accessible to the public via a teleconference phone link, and there will be Web-based access to information displayed at the meeting via computer/ projector. Attendance at the meeting will be limited due to space available. Name of Committee: Interagency Autism Coordinating Committee (IACC). Type of Meeting: Strategic Planning Implementation Working Group. Date: September 10, 2008. Time: 11 a.m. to 3 p.m. EDT. Agenda: To discuss future budgetary requirements for the IACC Strategic Plan for Autism Spectrum Disorder (ASD) Research. Place: National Institutes of Health, Building 1, Wilson Hall, Bethesda, MD 20892. Access Information: Conference Call and Webinar, Webinar Registration and Access Information: https://www1.gotomeeting.com/ register/550445924. To Access the Conference Call: Dial: Number: 888–455– 2920. Access Code: 3857872. Contact Person: Azik Schwechter, Ph.D., Office of Autism Research Coordination, Office of the Director, National Institute of Mental Health, NIH, 6001 Executive Boulevard, NSC Room 8203a, Bethesda, MD 20892–9669, 301–443–7163, IACCPublicInquiries@mail.nih.gov. Please Note: The workgroup meeting will be open to the public through a conference call phone number and a web presentation tool on the Internet. Individuals who participate using these electronic services and who need special assistance, such as captioning of the conference call or other VerDate Aug<31>2005 17:12 Aug 21, 2008 Jkt 214001 reasonable accommodations, should submit a request at least 2 weeks prior to the meeting. Members of the public who participate using the conference call phone number will be able to listen to the meeting but will not be heard. There may be an opportunity for members of the public to submit written comments during the workgroup meeting through the web presentation tool. Submitted comments will be reviewed after the meeting. If you experience any technical problems with the web presentation tool, please contact GoToWebinar at (800) 263–6317. To access the web presentation tool on the Internet the following computer capabilities are required: A. Internet Explorer 5.0 or later, Netscape Navigator 6.0 or later or Mozilla Firefox 1.0 or later; B. Windows 2000, XP Home, XP Pro, 2003 Server or Vista; C. Stable 56k, cable modem, ISDN, DSL or better Internet connection; D. Minimum of Pentium 400 with 256 MB of RAM (Recommended); E. Java Virtual Machine enabled (Recommended). Information about the IACC is available on the Web site: http://www.nimh.nih.gov/ research-funding/scientific-meetings/ recurring-meetings/iacc/index.shtml. Dated: August 15, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–19455 Filed 8–21–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive License: Diagnostics Based on Immune Reactions to Brother of the Regulator of Imprinted Sites (BORIS) National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), announces that the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in PCT Application No. PCT/US2007/77281, entitled ‘‘BORIS Isoforms and Methods of Detecting and Treating Disease’’ filed August 30, 2007 (E–117–2006/0–PCT– 02); EP Application No. 05799643.1, entitled ‘‘Method of Detecting Cancer Based On Immune Reaction To BORIS’’ filed September 21, 2005 (E–241–2004/ 0–EP–03); U.S. Application Serial No. 11/575,732, entitled ‘‘Method of Detecting Cancer Based On Immune Reaction To BORIS’’ filed March 21, PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 2007 (E–241–2004/0–US–04); U.S. Patent No. 7,375,206, entitled ‘‘Brother of The Regulator of Imprinted Sites (BORIS)’’ issued May 28, 2008 (E–227– 2001/0–US–03); and EP Patent Application No. 03743179.8, entitled ‘‘Brother of The Regulator of Imprinted Sites (BORIS)’’ filed September 17, 2004 (E–227–2001/0–EP–04) to Wellstat Diagnostics, Inc. The prospective exclusive territory may be worldwide, and the field of use may be limited to manufacture and sale of diagnostics for cancer and cancer predisposition. DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before October 21, 2008 will be considered. ADDRESSES: Requests for copies of the patent and/or patent applications, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Mojdeh Bahar, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804. Telephone: (301) 435–2950; Facsimile: (301) 402– 0220; E-mail: baharm@od.nih.gov. SUPPLEMENTARY INFORMATION: The above-mentioned patent applications describe the human protein Brother of Regulator of Imprinted Sites (‘‘BORIS’’), and a method of detecting cancer by monitoring BORIS expression or by detecting anti-BORIS antibodies. Dr. Victor V. Lobanenkov and colleagues at the National Institute of Allergy and Infectious Diseases discovered BORIS and its potential application as a cancer diagnostic. BORIS is a paralog of CCCTC-binding factor (‘‘CTCF’’), a transcription factor that also functions in chromatin insulation. The amino acid sequences of BORIS and CTCF contain eleven conserved zinc fingers each of which binds to DNA. BORIS protein can be detected in cancer cells, and importantly, it is one of a few cancertestis antigens that are immunogenic in humans. BORIS resides in 20q13.2, a region that is commonly amplified in many human cancers. Normally, BORIS mRNA can be detected in testis, but not in other human tissues. However, BORIS mRNA is detectable in over one hundred cancer cell lines representing most of the major forms of human tumors and is also detectable in primary breast cancer tumor samples, but not in controls. BORIS protein is misexpressed in cancer cell lines, and antibodies against BORIS have been detected in serum from patients with E:\FR\FM\22AUN1.SGM 22AUN1

Agencies

[Federal Register Volume 73, Number 164 (Friday, August 22, 2008)]
[Notices]
[Pages 49689-49690]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-19450]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Board of Scientific Counselors, NIDDK.
    The meeting will be closed to the public as indicated below in 
accordance with the provisions set forth in section 552b(c)(6), Title 5 
U.S.C., as amended for the review, discussion, and evaluation of 
individual intramural programs and projects conducted by the National 
Institute of Diabetes and Digestive and Kidney Diseases, including 
consideration of personnel qualifications and performance, and the 
competence of individual investigators, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Board of Scientific Counselors, NIDDK.
    Date: October 6-7, 2008.
    Time: October 6, 2008, 9 a.m. to 5 p.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: National Institutes of Health, Building 10, 10 Center 
Drive, 9S235, Bethesda, MD 20892.
    Time: October 7, 2008, 9 a.m. to 4 p.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: National Institutes of Health, Building 10, 10 Center 
Drive, 9S235, Bethesda, MD 20892.
    Contact Person: Ira W. Levin, PhD, Chief, Section on Molecular 
Biophysics, Division of Intramural Research, National Institute of 
Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, 
301-496-6844, iwl@helix.nih.gov.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition

[[Page 49690]]

Research; 93.849, Kidney Diseases, Urology and Hematology Research, 
National Institutes of Health, HHS)

    Dated: August 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
 [FR Doc. E8-19450 Filed 8-21-08; 8:45 am]
BILLING CODE 4140-01-P